Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the Company’s anti-von Willebrand factor (vWF) …
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
